Interferon-alpha administration enhances CD8+ T cell activation in HIV infection

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Type I interferons are crucial for innate immunity.
• In HIV infection, type I interferons have dual roles: inhibiting viral replication but also promoting immune activation, potentially accelerating disease progression.

Purpose of the Study:

• To investigate the impact of type I interferon (IFNα) on T cell activation in untreated HIV infection.
• To examine changes in T cell subsets, cell cycle, and activation markers during and after IFNα treatment.

Main Methods:

• Analysis of cryopreserved peripheral blood mononuclear cells from 10 HIV+ subjects in ACTG Study 5192.
• Flow cytometry was used to assess T cell activation markers (CD38, HLA-DR) on CD4+ and CD8+ T cells before, during, and after 12 weeks of IFNα therapy.

Main Results:

• IFNα treatment significantly increased the proportion of activated CD8+ T cells (CD38+HLA-DR+), from 11.7% at baseline to 24.1% after 12 weeks.
• Activated CD4+ T cell frequencies remained unchanged.
• A paradoxical increase in CD8+ T cell activation correlated with falling plasma HIV levels during interferon therapy.

Conclusions:

• Type I interferon administration enhances CD8+ T cell activation in individuals with HIV.
• These findings suggest that type I interferons may contribute to the heightened CD8+ T cell activation observed in HIV infection.